Research programme: purinoceptor P2X3 antagonists - NEOMEDAlternative Names: BLU-5937; NEO-5024; NEO-5937; P2X3 receptor antagonists - NEOMED
Latest Information Update: 07 Mar 2017
At a glance
- Originator AstraZeneca
- Developer NEOMED
- Class Small molecules
- Mechanism of Action Purinergic P2X3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cough; Pain; Visceral pain
- No development reported Interstitial cystitis